japanese%20encephalitis%20virus
JAPANESE ENCEPHALITIS VIRUS

Japanese encephalitis virus is an RNA flavivirus that causes virus encephalitis across Asia, the western Pacific region and parts of Australia.

It is transmitted in an enzootic cycle and the virus is transmitted to humans through the bite of infected Culex tritaeniorhynchus mosquitoes.

There is no specific antiviral treatment for Japanese encephalitis virus and management is mainly symptomatic treatment and supportive care.

Personal protection from mosquito bites in endemic areas and obtaining vaccination are the primary strategies to control Japanese encephalitis virus infection due to lack of specific antiviral therapy, high case fatality, and substantial morbidity.

Supportive Therapy

  • Mode of therapy for Japanese encephalitis virus infection are symptomatic treatment, supportive care and management of complications
  • There is no specific antiviral treatment for Japanese encephalitis virus infection
  • Hospitalization for supportive care and close observation is generally required
  • Careful nursing care and physiotherapy are needed to reduce the risk of bed sores, malnutrition and contractures
  • Rest, fluids and pain relievers are used to reduce fever and relieve some symptoms
  • In controlled clinical trials, corticosteroids, Interferon alpha-2a or Ribavirin did not improve clinical outcome
  • Supportive care for Japanese encephalitis patients should be emphasized on:
    • Control of intracranial pressure
    • Maintenance of adequate cerebral perfusion pressure
    • Seizure control
    • Prevention of secondary complications
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Infectious Diseases - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Tristan Manalac, 12 Feb 2020
Incorporating genotyping of human adenovirus (HAdV) infections in clinical practice may inform risk stratification and treatment decisions, according to a new Singapore study.
Tristan Manalac, 25 Oct 2019
Old age and lower white cell counts are significant risk factors for poor platelet recovery among dengue patients with thrombocytopaenia, according to a recent Singapore study.
Tristan Manalac, 19 Oct 2017
White matter (WM) integrity in HIV-infected children is compromised despite early antiretroviral therapy (ART) and viral load (VL) suppression, with damage persisting at 5 years of age and evidence of new damage present, a recent study has shown.
14 Feb 2020
A 10-day or 14-day sequential therapy strategy is more cost-effective than a conventional triple therapy in the management of patients with Helicobacter pylori infection, in addition to being more effective in terms of eradication of infection, as reported in a study from Egypt.